DNACA
Financiado
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision...
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effec...
With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever. However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Phase IIa clinical trials have shown strong effects in the treatment of HCCAA. We will now carry out a registration trial for commercialization in Iceland and POC studies in Europe to obtain NDA in familial dementia, thereby informing the treatment of Alzheimer’s Disease (60% of dementia cases), potentially changing the lives of millions for the better.
ver más
Duración del proyecto: 22 meses
Fecha Inicio: 2023-04-05
Fecha Fin: 2025-02-28
Fecha Fin: 2025-02-28
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-05
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
ARCTIC THERAPEUTICS EHF
No se ha especificado una descripción o un objeto social para esta compañía.
